Related references
Note: Only part of the references are listed.Strategies for Personalized Medicine-Based Research and Implementation in the Clinical Workflow
W. Lieb et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Implementing Personalized Medicine: Development of a Cost-Effective Customized Pharmacogenetics Genotyping Array
J. A. Johnson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis
Andrea L. Jorgensen et al.
PLOS ONE (2012)
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy
Benjamin D. Horne et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
J. A. Johnson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Genetic Warfarin Dosing Tables Versus Algorithms
Brian S. Finkelman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Emergency Hospitalizations for Adverse Drug Events in Older Americans
Daniel S. Budnitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Association of Apolipoprotein E Genotype with Duration of Time to Achieve a Stable Warfarin Dose in African-American Patients
Larisa H. Cavallari et al.
PHARMACOTHERAPY (2011)
Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing
P. Lenzini et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
Fumihiko Takeuchi et al.
PLOS GENETICS (2009)
CYP4F2 genetic variant alters required warfarin dose
Michael D. Caldwell et al.
BLOOD (2008)
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Gregory M. Cooper et al.
BLOOD (2008)
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
B. F. Gage et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements
CL Aquilante et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Pyrosequencing method for genotyping cytochrome P450CYP2C8 and CYP2C9 enzymes
MW Hruska et al.
CLINICAL CHEMISTRY (2004)
Share Paper
